SpectrumX expands its R&D division with the appointment of a microbiology team
Receive instant alerts when news is published about your stocks. Claim your one week free trial for StreetInsider Premium here.
- Internal microbiology laboratory mandated to accelerate the development of the product range and strengthen differentiation
- Experienced microbiologists will provide quality control of drug substances, perform analytical research on potential drugs, and advance new applications for a proprietary form of hypochlorous acid
- The introduction of the new team underscores SpectrumX’s commitment to stringent analytical and quality control methods, which will enable the company to bring its products to market faster and more efficiently.
LONDON–(BUSINESS WIRE)– SpectrumX, a UK-based pharmaceutical and healthcare company, today announces that it has appointed Chief Microbiology Officer, Annaliese Waite, BSc, and Microbiologist Heather Lloyd , MSc, LIBMS (Licentiate of the Institute of Biomedical Science). These appointments form a new microbiology team at SpectrumX and reinforce the company’s strategy to expand its product R&D division.
Waite brings extensive microbiology experience at major pharmaceutical companies, including AstraZeneca, where she developed rapid sterility tests for the Covid-19 vaccine. Most recently, she was a member of the technical team at Byotrol, an antimicrobial technology company, where she focused on R&D, including microbiological testing and conducting preparatory procedures to ensure quality standards. At SpectrumX, Waite will apply his industry expertise to expand the company’s product R&D capabilities by developing test methods, managing its laboratories and preparing a quality control program for SpectrumX’s products. This will allow the Company to more transparently implement the regulatory procedures necessary for the preparation of the marketing authorization.
Lloyd is experienced in evaluating the antimicrobial efficacy of industrial and cosmetic product samples, most recently as a microbiologist with Thor Specialties, a multinational manufacturer and distributor of biocides, flame retardants, personal care ingredients and other specialty chemicals. Lloyd’s efficacy testing expertise will inform and enhance the development and production of SPX-001, SpectrumX’s prospective anti-pathogen drug therapy that contains the Company’s patent-pending hypochlorous acid (HOCl) formulation . She also brings a particular interest and experience in antimicrobial resistance research, in which HOCl has shown great promise in terms of efficacy.
Damien Hancox, CEO of SpectrumX, said: “We are delighted to have appointed Annaliese and Heather to expand our product R&D capabilities at SpectrumX. The wealth of knowledge and insight that these talented individuals bring will support us on the path to bringing our products to market. These appointments signal our intention to strengthen our product R&D team and illustrate our commitment to bringing our products to market quickly and efficiently.
– ENDS –
About Spectrum X
SpectrumX is a UK-based healthcare and pharmaceutical company focused on bringing breakthrough therapy for respiratory infections to market and rolling out the world’s strongest hand sanitizer to the NHS and other healthcare customers. Both products use unique, patent-pending HOCl formulations. HOCl is naturally present in human white blood cells and is a key contributor in the immune response to infection. It is well tolerated in humans while being the most effective known disinfectant when used on surfaces. To learn more about SpectrumX, visit www.spectrumx.com.
Show source version on businesswire.com: https://www.businesswire.com/news/home/20220822005333/en/
Jeff Segvitch/Amy Stupavsky
+44 (0)203 488 7510
Comments are closed.